The FDA’s Commissioner’s National Priority Review Voucher (CNPV) pilot program is drawing renewed scrutiny as stakeholders argue the program lacks key operational details and could be redundant to existing expedited pathways. Critics cite uncertainty around candidate selection and whether senior FDA leadership is influencing decisions. Michael Abrams of Numerof & Associates and former FDA associate commissioner Peter Pitts (Center for Medicine in the Public Interest) both urged reconsideration, with Pitts arguing the program “can cease to exist.” The voucher framework, launched last June under former commissioner Marty Makary, is meant to streamline reviews for products tied to U.S. national priorities. Supporters, including biopharma companies eager for faster approvals, have backed the intent of the initiative, but the debate centers on governance and transparency. So far, the program has distributed vouchers for therapies spanning cancer, rare disease, mental health and other priority areas.